Chapman University

Chapman University Digital Commons
Pharmacy Faculty Articles and Research

School of Pharmacy

4-27-2021

Suppression of Human Coronavirus 229E Infection in Lung
Fibroblast Cells via RNA Interference
Hamidreza Montazeri Aliabadi
Jennifer Totonchy
Parvin Mahdipoor
Keykavous Parang
Hasan Uludağ

Follow this and additional works at: https://digitalcommons.chapman.edu/pharmacy_articles
Part of the Amino Acids, Peptides, and Proteins Commons, Biological Phenomena, Cell Phenomena,
and Immunity Commons, Chemical and Pharmacologic Phenomena Commons, Epidemiology Commons,
Genetic Structures Commons, Medical Cell Biology Commons, Medicinal and Pharmaceutical Chemistry
Commons, Nucleic Acids, Nucleotides, and Nucleosides Commons, Other Pharmacy and Pharmaceutical
Sciences Commons, Other Public Health Commons, Pharmaceutical Preparations Commons, and the
Pharmaceutics and Drug Design Commons

Suppression of Human Coronavirus 229E Infection in Lung Fibroblast Cells via
RNA Interference
Comments
This article was originally published in Frontiers in Nanotechnology, volume 3, in 2021. https://doi.org/
10.3389/fnano.2021.670543
This scholarship is part of the Chapman University COVID-19 Archives
Archives..

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.

Copyright
The authors

ORIGINAL RESEARCH
published: 27 April 2021
doi: 10.3389/fnano.2021.670543

Suppression of Human Coronavirus
229E Infection in Lung Fibroblast Cells
via RNA Interference
Hamidreza Montazeri Aliabadi 1,2*, Jennifer Totonchy 1, Parvin Mahdipoor 1,
Keykavous Parang 1,2* and Hasan Uludağ 3,4,5*
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Despite extensive efforts to repurpose approved drugs, discover new small molecules, and
develop vaccines, COVID-19 pandemic is still claiming victims around the world. The
current arsenal of antiviral compounds did not perform well in the past viral infections (e.g.,
SARS), which casts a shadow of doubt for use against the new SARS-CoV-2. Vaccines
should offer the ultimate protection; however, there is limited information about the
longevity of the generated immunity and the protection against possible mutations.
This study uses Human Coronavirus 229E as a model coronavirus to test the
hypothesis that effective delivery of virus-speciﬁc siRNAs to infected cells will result in
lower viral load and reduced cell death. Two different categories of nucleic acid delivery
systems, Peptide/Lipid-Associated Nucleic Acids (PLANAs) and lipophilic polymers, were
investigated for their toxicity in human lung ﬁbroblast cells and their ability to deliver speciﬁc
siRNAs targeting Spike and Envelope proteins in order to prevent cell death in infected
cells. Selected siRNAs were effectively delivered to human lung ﬁbroblast cells with
negligible toxicity. Cell death due to viral infection was signiﬁcantly reduced with
individual and combinatorial silencing of selected viral proteins. The combinatorial
silencing of Spike and Envelope proteins restored the cell viability completely and
eliminated plaques in the investigated system. Our cell culture data indicate promising
results for the RNAi based approach as an alternative antiviral treatment.
Keywords: coronavirus, RNA inteference, lung ﬁbroblast cell, delivery, PLANA

INTRODUCTION
COVID-19 is an emerging disease with little history of therapeutic development. The previous
experience with other viral epidemics such as SARS and MERS have revealed difﬁculties associated
with the treatment of similar viral infections. Based on our analysis of the current activity, the
researchers are pursuing the two main approaches to manage the current epidemic. On one hand,
small molecular drugs are being extensively explored to repurpose them for the treatment of SARSCoV-2. It is hoped that certain pre-approved drugs will prevent the replication of SARS-CoV-2 and
will be widely available since they are approved for human use. It is likely that effective drug hits will
emerge from this activity [in one of the ﬁrst published studies, 29 FDA-approved drugs were
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identiﬁed as “hits” based on their protein interactions maps
(Gordon et al., 2020)]. Some of the existing antiviral
compounds may also be promising. However, the current
arsenal of antiviral compounds based on small molecular
drugs has been mostly ineffective in the past viral infections
(indicated by lack of FDA-approved drugs for treatment of those
infections). Thus, there is a chance that the approved drugs will
not be effective against the new SARS-CoV-2. Some high-proﬁle
drugs are already failing in initial studies [e.g.,
hydroxychloroquine (Cavalcanti et al., 2020; Lyngbakken et al.,
2020)], and no obvious candidates are emerging. Even remdesivir,
which showed promising results in vitro, has failed to produce a
statistically signiﬁcant difference in the clinical status of COVID19 patients compared to standard care in large clinical studies
(Spinner et al., 2020; Wang et al., 2020). However, the FDA
authorized remdesivir for COVID-19 treatment on October 22nd,
2020, under emergency use (U.S. Food and Drug
Administration). Also, vaccines are being extensively explored
since they could offer ultimate protection against the SARS-CoV2 infection. One can inject a viral protein, the attenuated virus, or
DNA/mRNA coding for viral proteins, and induce immunity
against the virus. Despite the fact that there were no vaccines
available against any of the coronavirus epidemics in the past
(e.g., SARS or MERS; which could be largely due to more limited
outbreak), mRNA vaccines against the SARS-CoV-2 from PﬁzerBioNTech and Moderna have been recently authorized for
emergency use in the United States and other countries.
Although more extensive studies are underway, the current
evidence suggests that the immune response generated by
these vaccines seems durable and initial protection is readily
observed in clinical studies. Long term immunity remains to be
investigated since it is still early days of vaccine use at the time this
study is conducted. Moreover, the global dissemination of SARSCoV2 is extensive enough that, even with highly effective vaccines
and good vaccine uptake, vaccination will not be sufﬁcient to
eliminate clinically relevant infections in the short-term. Thus,
there is still urgent need for therapeutic agents to mitigate the
virus pathogenesis and minimize physiological damage in
infected patients.
Using RNAi approaches as an antiviral strategy is not
unprecedented. Past experiences with SARS have indicated the
efﬁciency of siRNA therapy as a potential antiviral approach. In
2005, Wu et al. reported that siRNAs targeting spike protein
(S-protein) of SARS-CoV cause 85–90% reduction in viral load as
assessed by PCR analysis (Wu et al., 2005). The efﬁciency of this
approach has also been veriﬁed by using short hairpin RNAs
(shRNA) against SARS-CoV (Qin et al., 2004; Zhang et al., 2004).
RNA-dependent RNA polymerase (RDRP) (Meng et al., 2006),
nucleocapsid (N-protein) (Zhao et al., 2005), envelope
(E-protein) (Meng et al., 2006), and membrane (M-protein)
(Qin et al., 2007) are among other targets explored in SARSCoV infection with different degrees of success. In separate
studies screening 48 siRNAs targeting different regions of
SARS-CoV genome, S-protein, and open reading frame 1b
(ORF1b) were identiﬁed as effective siRNAs against the viral
infection and further validated in Rhesus macaque primates (Li
et al., 2005; Tang et al., 2008; Uludağ et al., 2020).
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Developing RNAi-based drugs for SARS-CoV-2 is likely to
offer more speciﬁc therapies and can potentially be directed
against two different categories of targets: 1) viral proteins
essential in survival and replication of SARS-CoV-2, and 2)
host factors involved in cellular entry and trafﬁcking of the virus.
We recently reviewed these RNAi-based strategies and their
prospect in COVID-19 treatment in (Uludağ et al., 2020).
Herein, we report on the former approach due to a lower
chance of complications that could result from silencing host
proteins and controversy over the efﬁciency of targeting
proteins such as angiotensin-converting enzyme 2 (ACE2).
We have previously reported efﬁcient small interfering RNA
(siRNA) delivery to cancer cells via speciﬁcally designed
polymers (Aliabadi et al., 2011; Aliabadi et al., 2013; Aliabadi
et al., 2020) and cell-penetrating peptides (Do et al., 2017;
Mozaffari et al., 2019). We also recently reported a novel
delivery system called Peptide/Lipid-Associated Nucleic Acids
(PLANAs), which is based on the incorporation of speciﬁcally
designed cell-penetrating peptides in a multi-component
nanoparticle (Hall et al., 2021a) (United States patent
application number 17170785). The structure of the peptides
and the proposed structure of PLANAs (and how they
encapsulate nucleic acids) are presented in Supplementary
Figures S1, S2, respectively. In this study, we evaluated the
safety of these two siRNA carriers in human lung ﬁbroblast cells,
the efﬁciency of the carriers in internalizing the siRNA into
these cells, and the efﬁciency of this approach in minimizing
Human Coronavirus 229E-induced cell death and plaque
formation.

MATERIALS AND METHODS
Materials

™

Lipofectamine
2000
was
purchased
from
Life
Technologies (Grand Island, NY, United States). 1,2Dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), 1,2dioleoyl-3-trimethylammonium-propane (DOTAP; chloride
salt), cholesterol, phosphatidylcholine, and Avanti Mini
Extruder were provided by Avanti Polar Lipids, Inc.
(Alabaster, AL, United States). Cell Counting 8 (CCK8)
KIT was obtained from Biotool (Houston, TX, United States;
also known as WST-8). VECTASHIELD VIBRANCE with
DAPI (used to stain the cell nuclei) was obtained from
Vector Laboratories (Burlingame, CA, United States). All
other reagents and consumables, including cell culture
requirements and Texas Red (used to stain cell membrane)
were provided by VWR (Radnor, PA, United States).
All Stars negative control siRNA labeled with Alexa
Fluor 488 (AF488; Catalogue number 1027292; sequence:
proprietary) was purchased from Qiagen (Valencia, CA,
United States). The siRNAs targeting spike (S) and envelope
(E) proteins were designed based on the viral RNA sequence
reported in literature (Raabe et al., 1990; Zhang et al., 2014)
using the Integrated DNA Technologies (IDT) primer design
software and were provided by IDT with the following
sequences:

2
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Spike protein: Forward – 5′-GUU AAA UUU GGC AGU GUA
UGU UUU UCG-3′
Reverse – 5′-CGA AAA ACA UAC ACU GCC AAA UUU
AAC-3′
Envelope protein: Froward – 5′GUU AAA UUU GGC AGU
GUA UGU UUU UCG-3′
Reverse – 5′CGA AAA ACA UAC ACU GCC AAA UUU
AAC-3′

Treatment (NT; normal saline) and scrambled siRNA
delivered by Leu-Fect B (12-18-6A and 12-18-9A),
2000, and PLANAs. The siRNA/
Lipofectamine
complexes and siRNA/polymer polyplexes
Lipofectamine
were prepared according to the manufacturers’ guidelines.
Brieﬂy, Lipofectamine and siRNA were diluted in FBS- and
antibiotic-free OPTIMEM and were mixed. After 20 min.
incubation at ambient temperature, the cell culture medium
was removed, and the siRNA complexes were added to the
wells in OPTIMEM. After 6 h of incubation at 37°C, the
complexes were removed, and the cell culture medium was
added to the wells. For polyplexes, polymer and siRNA were
mixed in normal saline, and after 30 min of incubation in ambient
temperature, the polyplexes were added to the cells. For each
carrier, siRNA was delivered at two ﬁnal concentrations (in
triplicates): 50 and 100 nM, which also showed exposure to
two different carrier concentrations. Cells were incubated in
37 C and 5% CO2 for 48 h after exposure. A Cell Counting 8
(CCK8) KIT (also known as WST-8) was used to evaluate the
potential toxicity of the formulations on the viability of the MRC5 cells. After the 24 h incubation period, 10 uL of CCK solution
(Cat. #B34304) was added to each well. The plates were incubated
at 37 C for 1 h, after which the absorbance was measured at
450 nm using a SpectraMax M5 UV VIZ Plate Reader to
determine the percentage of viable cells compared to the no
treatment group (after eliminating the signal from “Blank” wells
containing cell-less medium with CCK-8 solution added).

™
™

™

Methods
Carriers
The polymeric carrier used in this study was LeuFect B (batch
numbers 12-18-6A and 12-18-9A) from RJH Biosciences
(Edmonton, Canada). The components and preparation methods
for PLANAs have been previously reported (Hall et al., 2021a).
Brieﬂy, PLANA nanoparticles were prepared by incorporating
siRNA(s) and linear R5K2 peptide-stearic acid conjugate (LPC18) into the selected lipid composition. The peptide and
siRNA were mixed in the aqueous portion of the formulation,
while 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE),
cholesterol, and phosphatidylcholine were mixed in ethanol. The
two portions were mixed, and PLANA nanoparticles were formed
by passing the mixture through an Avanti Mini Extruder (Alabaster,
Alabama) with a 100 nm membrane ﬁlter 50 times to create
nanoparticles with the approximate size of 100 nm.
Cell Line
Human MRC-5 lung ﬁbroblast cells (ATCC® CCL-171 ) were
thawed and subcultured using Dulbecco’s Modiﬁed Eagle
Medium (DMEM) low glucose. Cells were incubated in 37°C
and 5% CO2 for the entire growth time. Cells were expanded
when reached ∼80% conﬂuency and were replaced after 30
expansions or 90 days (whichever earlier).

™

Cellular Internalization
MRC-5 cells were seeded in 24-well plates at ∼50% conﬂuency the
day before the experiment and were treated with one of the
following study groups: Normal saline (no treatment; NT), free
AF488-siRNA, AF488-siRNA/polymer complexes, PLANA
2000
encapsulated AF488-siRNA, or Lipofectamine
encapsulating AF488-siRNA (all in triplicates). The ﬁnal
concentration of delivered siRNA was 36 nM for all treatment
groups. After exposure to siRNA, cells were incubated at 37°C and
5% CO2 for 24 h, and then the media was removed, and the cells
were detached using 0.05% trypsin (for Lipofectamine the
manufacturer’s protocol was followed). Trypsinized cells were
ﬁxed using 3.7% formaldehyde in 1X PBS, and each sample was
evaluated using FACSVERSE ﬂow cytometer (BD Biosciences;
San Jose, CA). The ﬂuorescein isothiocyanate (FITC) channel was
used to quantify cell-associated ﬂuorescence. The percentage of
cells positive for ﬂuorescence signal and the mean ﬂuorescence of
the cell population were calculated following each ﬂow cytometry
analysis using the calibration of the signal gated with No
Treatment cells in order to eliminate autoﬂuorescence of
approximately 1% of the population in “no treatment” group.

™

hCoV-229E Virus Preparation
Human Coronavirus 229E was obtained from ATCC (VR-740).
The commercial stock was used to infect MRC-5 cells and initially
ampliﬁed via two rounds of supernatant transfer (p1 and p2).
50 ml of p2 supernatant was retained as a seed stock. Final virus
stock for experiments was produced by infecting 5x T-185 ﬂasks of
MRC-5 cells with 1 ml each of p2 seed stock in DMEM+2% FBS.
Infection was allowed to proceed for 5 days until 90% of MRC-5
cells showed cytopathic effect. Culture supernatant was collected,
and cell material was pelleted via centrifugation at 1000 ×g for
15 min. The clariﬁed supernatant was kept on ice. Fresh serum-free
DMEM was added to the culture vessels, and remaining cells were
harvested using a cell scraper and pelleted as above. The two cell
pellets were combined in a total of 5 ml of serum-free DMEM and
subjected to three rapid freeze-thaw cycles. Cell lysates were added
back to the clariﬁed culture supernatant, and 1 ml aliquots of virus
preparation were stored at -80 C for experiments. p3 stock virus
was quantitated via TCID50 method on MRC5 cells using the MTT
assay described below.

Confocal Microscopy
A sterile cover lip was placed at the bottom of each well in 6-well
plates, and the cover slips were covered with a 10% FBS solution
in DMEM and were incubated for 30 min at 37 C to enhance the
cell adherence to the cover slip surface. MRC-5 cells were then
seeded in the wells at a conﬂuency of ∼70% and were incubated
overnight at 37 C and 5% CO2. Cells were then treated with one of

Cytotoxicity
MRC-5 cells were seeded in 96-well plates at ∼50% conﬂuency
24 h before the experiment. The study groups included: No
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™

one hour of infection at 37 C, overlay media containing 1%
Agarose in DMEM was heated to 50 C. Immediately prior to
overlay, 4% FBS was added to the overlay media, 500 μL of
overlay was added to each well, and plates were cultured for
4 days at 37 C, 5% CO2. At 4 dpi, wells were ﬁxed by adding 1 ml
of 10% formaldehyde and incubating at 37 C overnight. After
ﬁxation, media was removed, and monolayers were stained with
1% crystal violet in 20% ethanol for 15 min at room
temperature, followed by several rinses with diH2O and
drying before plaques were counted.

the following groups: free AF488-siRNA, Lipofectamine 2000
encapsulating AF488-siRNA, AF488-siRNA/polymer complexes,
or PLANA encapsulated AF488-siRNA (all in triplicates). Cells
were then incubated for 24 at 37 C and 5% CO2, after which the
media was removed, and cells were washed three times with one X
PBS. Cells were then ﬁxed with 3.7% formaldehyde in 1X PBS for
10 min. The ﬁxed cells were rinsed three times in 1X PBS for
5 min, after which Texas Red Phalloidin solution (40 uL and
10 mg BSA in 10 ml of 1X PBS) was added to the cells to stain the
cell membrane. Stained cells were incubated at room temperature
for 1 h, and were then washed three times with 1X PBS for 5 min.
One drop of VECTASHIELD VIBRANCE with DAPI was added
to each slide to stain the nucleus, and the coverslips were placed
face down on slides, without air bubbles, and were stored
overnight away from light to dry. Once dry, a Nikon A1R
high-deﬁnition resonant scanning confocal microscope and a
NIS-Elements software (AR 4.30.02, 64bit) were used to image
the cells.

Statistical Analysis
Student t-test (two-ways, Unequal variance) was used in mean
comparisons between two groups (e.g., the toxicity of each
delivery system compared to the no treatment group). Oneway ANOVA with Tukey as Post Hoc test and signiﬁcance
level of 0.05 was used for statistical analysis of means between
multiple groups (e.g., the cellular internalization for different
carriers).

hCoV-229E Inhibition via MTT Assay
The antiviral studies were performed to test the efﬁcacy of
targeting spike and envelope proteins individually and
simultaneously, to investigate the potential beneﬁt of
combinatorial silencing of two viral targets via delivering a
cocktail of siRNAs. For this set of studies, remdesivir was used
as a positive control, and media only was used as a negative
control. Polymer/siRNA complexes or PLANAs were prepared to
deliver 100 nM of siRNA targeting mRNA sequence for spike
protein expression, 100 nM of siRNA targeting mRNA sequence
for envelope protein, or a combination of 50 nM of each siRNA.
Treatments were added to the plate at 1 h prior to infection. P3
virus stock was added at 2 TCID50 units per well in a total of
100 µL of serum-free DMEM and incubated at 37 C for one hour.
After the initial incubation, an additional 100 µL of DMEM
containing 4% FBS was added to each well to make a ﬁnal
concentration of 2% FBS and incubated at 37 C, 5% CO2. At
7 days post-infection, cell viability was assessed using MTT assay
(Promega) according to manufacturer instructions. Brieﬂy, media
was removed and discarded to leave 100 µL in each experimental
well. MTT reagents were mixed and added directly to cultures
(20 µL/well) and allowed to incubate for 1 h at 37 C. 50µL of 10%
SDS was then added to stop the MTT reaction and inactivate the
virus for analysis. Inactivation was allowed to proceed for 18 h at
room temperature. After inactivation, the MTT colorimetric
signal was analyzed using a Spectramax M5 plate reader.

RESULTS AND DISCUSSION
Cytotoxicity
The toxicity of the siRNA delivery system plays a crucial role in the
safety proﬁle of this approach in a clinical setting. Since the
proposed approach could potentially be used via the inhalation
route, especially in the early stages of the SARS-CoV-2 infection,
we selected MRC-5 human lung ﬁbroblast cells for our toxicity
experiments. The cell viability results after 24 h exposure to
different carriers are summarized in Figure 1. While
Lipofectamine (added to the study design as a commercially
available siRNA carrier) showed a drop in cell viability at 100 nM
of siRNA concentration (∼67% viability after 24 h exposure),
neither the polymer complexes nor the PLANA formulation
showed a cell viability of less than 85% at this siRNA
concentration. The cell viability was not <100% for the PLANA
formulation at both siRNA concentrations.
The toxicity of siRNA delivery systems has been a limiting
factor for their clinical use as well as extensive applications
in vitro. For instance, the more efﬁcient polymeric carriers are
often cytotoxic (Wightman et al., 2001; Whitehead et al., 2009;
Aliabadi et al., 2011; Aliabadi et al., 2012). Also, while positively
charged lipids are usually more efﬁcient in siRNA delivery than
neutral lipids, they are also more toxic (Xue et al., 2015;
Lechanteur and et al., 2018). We have previously reported on
the cytotoxicity of similar lipopolymer/siRNA complexes with
breast cancer cell lines (Aliabadi et al., 2011; Aliabadi et al.,
2020) and primary human cells (Landry et al., 2016; ValenciaSerna et al., 2019). We also reported cytotoxicity of different
PLANA formulations in MDA-MB-231 triple-negative human
breast cancer cells, as well as a variety of non-tumorigenic
cell lines, including myocardium cells and hepatocytes (Hall
et al., 2021b). Those studies also demonstrated a negligible effect
of the selected PLANA formulation (cited as formulation D
incorporating LP-C18) on cell viability up to 100 nM of siRNA
concentrations.

™

hCoV-229E Inhibition via Plaque Reduction Assay
MRC-5 cells were seeded in 24-well plates at 1 × 105 cells per
well 24 h before the experiment. Polymer/siRNA complexes or
PLANAs were prepared to deliver 100 nM of siRNA targeting
mRNA sequence for spike protein expression, 100 nM of siRNA
targeting mRNA sequence for envelope protein, or a
combination of 50 nM of each siRNA and were added to the
wells one hour prior to infection. 5-fold dilutions of p3 229E
virus stock in 500 µL of serum-free DMEM were then added in
triplicate such that, for each treatment condition, three wells
were infected at TCID50 8, 1.6, 0.32, and Mock (no virus). After
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FIGURE 1 | The cytotoxicity of the selected siRNA/carriers in human MRC-5 lung ﬁbroblast cells quantiﬁed using the CCK assay. No statistically signiﬁcant
difference was observed in the viability of cells exposed to either of the polyplexes or PLANA compared to cells exposed to normal saline (No Treatment, or NT).
* indicates that the viability of the cells exposed to 100 nM of siRNA delivered with Lipofectamine™ was signiﬁcantly lower compared to NT group.

FIGURE 2 | The level of cellular internalization of AlexaFluor488-labeled siRNA in human MRC-5 cells using the selected carriers. All Selected delivery systems included
in the study created mean ﬂuorescence values comparable to Lipofectamine™ (included as positive control). * indicates statistically signiﬁcant difference with PLANA group
(α  0.013). ** indicates signiﬁcant difference with both PLANA (α  0.002) and LipofectamineTM (α  0.034) groups. One-way ANOVA was used for statistical analysis.

Cellular Internalization

The cellular internalization was visualized using confocal
microscopy and the results were conﬁrmed by ﬂow cytometry
(Figure 3). The effective internalization of ﬂuorescent-labeled
siRNA can be observed for both Lipofectamine and PLANA
groups, where the AlexaFluor488-labeled siRNA were mostly
conﬁned to the cytoplasmic component (lipopolymers were not
used in this study). Cellular internalization is one of the major
characteristics indicating the efﬁciency of a siRNA carrier (along
with protein silencing). Many different carriers have shown efﬁcient
cellular internalization in vitro; however, the level of internalization is
usually dependent on the cell type and not universal in a wide
spectrum of cell lines. We previously reported encapsulation
efﬁciency, protection against enzymatic degradation, and efﬁcient

Internalization of free siRNA without a carrier into target cells is
usually negligible, which is observed in our experiments as well
(Figure 2). Lipofectamine increased the internalization of siRNA
into MRC-5 signiﬁcantly, as expected. The mean ﬂuorescence
observed in cells exposed to AF488-siRNA-encapsulated PLANA
was higher than the ﬂuorescence observed in Lipofectamine group
(1437 vs. 1260); however, the difference was not statistically
signiﬁcant (one-way ANOVA; α  0.157). The two polymers 1218-6A and 12-18-9A included in the study gave siRNA uptake that
was comparable to Lipofectamine . However, the difference in
internalization between the polymer groups and Lipofectamine
group was statistically signiﬁcant (α  0.034; Figure 2).

™

™

™
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FIGURE 3 | The confocal microscopy images of AF488-labeled siRNA (green channel) delivered to MRC-5 cells by Lipofectamine and PLANAs as compared to free
AF488-labeled siRNA. DAPI (blue channel) and Texas Red (Red channel) were used to dye the nuclei and cell membranes, respectively.

cellular uptake of siRNA formulated with PLANAs, which
demonstrated >98% encapsulation efﬁciency and should high
stability in the invitro studies (Hall et al., 2021a). The release
proﬁle of this formulation (tested by dialysis method vs. DI water
as receiving phase) showed ∼20 and 38% siRNA release after 24 and
72 h. The release in the cytoplasm is expected to be much faster due
to dissociation of the nanoparticles as a result of dilution and/or
displacement by other negatively charged components inside the
cells. Leu-Fect B reagent have also shown near complete
encapsulation and protection against enzymatic degradation for
at least 24 h (information provided by the supplier). We also
have reported the internalization of ﬂuorescence-labeled siRNA
in MDA-MB-231 triple-negative breast cancer cell lines, where
we observed the most efﬁcient cellular internalization for PLANA
D formulation (the selected composition for the present study),
which showed comparable cellular uptake to Lipofectamine (Hall
et al., 2021a). This conﬁrms efﬁcient cellular internalization into
human lung ﬁbroblast cells, which are the target cells for the purpose
of this study.

delivered to the cells. Remdesivir was used as the positive control
in this set of studies.
The siRNA delivery (in the absence of viral infection) did not
affect the cell viability signiﬁcantly, which again conﬁrmed the
minimal cytotoxicity of the siRNA treatments on the lung cells.
The lowest viability observed in the normal MRC-5 cells was in
the cells exposed to E-protein siRNA lipopolyplex (∼81 and ∼89%
viability for 100 nM of siRNA delivered by 1.2-18-6A and 1.2-189A, respectively: Figure 4). Infecting MRC-5 cells with hCoV229E decreased the viability to ∼21%, clearly indicating the
cytopathic effect of hCoV-229E infection on MRC-5 cells. In
hCoV-229E-infected cells, delivering S-protein targeting siRNA
preserved cell viability to 80, 79, and 88% with 100 nM siRNA
delivered by 12-18-6A, 12-18-9A, and PLANAs, respectively.
Targeting E-protein was less effective in preserving cell
viability for all selected delivery systems (54, 45, and 50% cell
viability with 100 nM siRNA delivered by 12-18-6A, 12-18-9A,
and PLANAs, respectively). Silencing S-protein and E-protein
simultaneously (50 nM for each siRNA) completely restored cell
viability for all three delivery systems. When at 50 nM siRNA
combinations (25 nM of each siRNA), cell viability was increased
to 90-100% for 12-18-6A, 12-18-9A, and PLANAs. Treating the
hCoV-229E-infected MRC-5 cells with 5 μM remdesivir restored
the viability to 92% (Figure 4D).
The efﬁciency of the reported approach should be additionally
evaluated by quantifying the viral RNA load in infected cells using
real-time PCR. However, we demonstrated effective internalization
of siRNA in MRC-5 cells in this manuscript and have previously
reported the silencing efﬁciency of the selected delivery systems in
different cell lines after delivering the siRNA cargo to the
cytoplasm (Aliabadi et al., 2020; Hall et al., 2021a; Plianwong

™

Antiviral Effect
We assessed the viability of viral transduced cells and plaque
formation to determine the effect of siRNA delivery in inhibiting
viral infection on MRC-5 cells. The viability of healthy and
hCoV-229E-infected MRC-5 cells was evaluated using the
MTT assay after siRNA delivery targeting S-protein, E-protein,
or a combination of both (each representing half of the
concentration compared to individual siRNA groups) in a
variety of concentrations (ranging from 25 to 100 nM of total
siRNA). The untreated MRC-5 cells were included to conﬁrm the
safety proﬁle observed in cytotoxicity studies when siRNAs were
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FIGURE 4 | Cell viability of healthy (no virus or NV) and hCoV-229E-infected (Virus) MRC-5 cells after delivering 25, 50, and 100 nM of siRNA targeting Spike (S),
Envelope (E), or a combination of both siRNAs (1:1 ratio) using 12–18-6A (A), 1.2–18-9A (B), PLANAs (C), plus remdesivir as positive control (D). Infecting the cells with
hCoV-229E diminished the cell viability to 21% (viability at 0 nM siRNA). While delivering S or E targeting siRNA restored the cell viability, delivering the combination of the
siRNAs completely preserved cell viability, even at 50 nM total siRNA concentration.

FIGURE 5 | Targeting S-protein and E-protein via PLANAs completely eliminated plaques seen at 8 TCID50 units per well in no treatment group (black arrows).
Experiments were conducted in triplicates.

et al., 2020). Also, the increase in the functional outcome of siRNA
treatment in restoring the cell viability with increasing siRNA
concentration presents a dose-response effect in line with the
expected direct causal relationship.
Finally, we used plaque assay to conﬁrm the efﬁciency of the
siRNA approach in preventing plaques formed in MRC-5
monolayers as a result of hCoV-229E-infection. The plaque
reduction neutralization test (PRNT) is considered a “gold
standard” in the evaluation of antiviral strategies used against
SARS-CoV-2 infections (Padoan et al., 2020; Perera et al., 2020; Xie
et al., 2020) and other viral infections (McLaughlin et al., 2020; Yau
et al., 2020). Using the PLANA-delivered combination of siRNAs
targeting S-protein and E-protein completely eliminated plaques
that were observed in non-treated cell cultures (Figure 5).
The deployment of the siRNA as an alternative approach to
upper respiratory tract viral infections is not unprecedented.

Frontiers in Nanotechnology | www.frontiersin.org

Many manuscripts reviewed the possibility of using RNA
interference (RNAi) as a therapeutic approach against COVID19 (Itani et al., 2020; Le et al., 2020; Piyush et al., 2020; Shaffer,
2020; Yu et al., 2020). We also reviewed the siRNA-based
strategies used in the past coronavirus infections and the
prospects of such strategies in combating SARS-CoV-2
pandemic (Uludağ et al., 2020). A recent paper by Lundstrom
has also reviewed viral vectors in delivering other RNA
interference mediators (e.g., shRNA) as a therapeutic approach
in a variety of viral infections (Lundstrom, 2020). Since the start of
pandemic in 2019, pharmaceutical companies are also exploring
this approach as a therapy against SARS-CoV-2 infection, and
publications in this regard are expected to appear soon. We
previously reported siRNA delivery by the lipopolymers as an
effective approach in several cancer models [reviewed in (Bahadur
K.C. et al., 2017) and (Landry et al., 2015)] and recently shown
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PLANAs to be effective in silencing two model proteins (Src and
kinase RPS6KA5) in MDA-MB-231 breast cancer cells (Hall et al.,
2021b).
In conclusion, we showed the efﬁciency of an siRNA-based
anti-viral approach in vitro in eliminating the damage caused in
MRC-5 lung ﬁbroblast cells by hCoV-229E-infection. We are
currently exploring the efﬁciency of this approach in vitro and in
vivo against SARS-CoV-2 infection. As a treatment in a clinical
setting, the siRNA would be delivered after the infection
occurred, while we implemented the siRNA treatment at the
same time as virus infection in this study. However, due to the
high viral load used in the viability test approach (to complete
the study in a reasonable timeframe), handling the infection
would be more difﬁcult if the siRNA was introduced after the
viral replication (note that the plaque test used here is performed
using a lower viral load to avoid complete eradication of the
cell monolayer). While this approach can be designed as a
preventive measure to slow the spread of the virus infection,
we would implement a more clinically relevant approach in
animal studies, where the siRNA administration would start
after animal model is infected. Although the challenges facing
systemic delivery of siRNA have slowed extensive use of RNAibased therapeutics in clinics, delivering siRNA via inhalation
route could be a simpler alternative in the treatment of COVID19 patients. In order to ensure safety and efﬁciency of this
approach via inhalation route, however, we are designing
experiments in human bronchial epithelial cells using a
model reported previously by Wang et al. (2000).
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(2017). Nucleic Acid Combinations: A New Frontier for Cancer Treatment.
J. Control. Release 256, 153–169. doi:10.1016/j.jconrel.2017.04.029
Cavalcanti, A. B., Zampieri, F. G, Rosa, R. G, Azevedo, L. C. P, Veiga, V. C, Avezum,
A, et al. (2020). Hydroxychloroquine with or without Azithromycin in MildTo-Moderate Covid-19. N. Engl. J. Med. 383 (21), 2041–2052. doi:10.1056/
NEJMoa2019014

Frontiers in Nanotechnology | www.frontiersin.org

8

April 2021 | Volume 3 | Article 670543

Aliabadi et al.

Coronavirus Suppression via RNA Interference

Le, T. K., Paris, C., Khan, K. S., Robson, F., Ng, W-L., and Rocchi, P. (2020). Nucleic
Acid-Based Technologies Targeting Coronaviruses. Trends Biochem. Sci.
S0968-0004 (20), 30295–4. doi:10.1016/j.tibs.2020.11.010
Lechanteur, A., Sanna, V., Duchemin, A., Evrard, B., Mottet, D., Piel, G., et al.
(2018). Cationic Liposomes Carrying siRNA: Impact of Lipid Composition on
Physicochemical Properties, Cytotoxicity and Endosomal Escape.
Nanomaterials (Basel) 8 (5), 270. doi:10.3390/nano8050270
Li, B.-j., Tang, Q., Cheng, D., Qin, C., Xie, F. Y., Wei, Q., et al. (2005). Using siRNA
in Prophylactic and Therapeutic Regimens against SARS Coronavirus in
Rhesus Macaque. Nat. Med. 11 (9), 944–951. doi:10.1038/nm1280
Lundstrom, K. (2020). Are Viral Vectors Any Good for RNAi Antiviral Therapy?
Viruses 12 (10), 1189. doi:10.3390/v12101189
Lyngbakken, M. N., Berdal, J-E., Eskesan, A., Kvale, D., Olsen, I. C., Rueegg, C. S.,
et al. (2020). A Pragmatic Randomized Controlled Trial Reports Lack of
Efﬁcacy of Hydroxychloroquine on Coronavirus Disease 2019 Viral
Kinetics. Nat. Commun. 11 (1), 5284. doi:10.1038/s41467-020-19056-6
McLaughlin, M. M., Ma, Y., Scherzer, R., Rahalkar, S., Martin, J. N., Mills, C., et al.
(2020). Association of Viral Persistence and Atherosclerosis in Adults with
Treated HIV Infection. JAMA Netw. Open 3 (10), e2018099. doi:10.1001/
jamanetworkopen.2020.18099
Meng, B., Lui, Y.-w., Meng, S., Cao, C., and Hu, Y. (2006). Identiﬁcation of Effective
siRNA Blocking the Expression of SARS Viral Envelope E and RDRP Genes.
Mol Biotechnol 33 (2), 141–148. doi:10.1385/mb:33:2:141
Mozaffari, S., Bousoik, E., Amirrad, F., Lamboy, R., Coyle, M., Hall, R., et al. (2019).
Amphiphilic Peptides for Efﬁcient siRNA Delivery. Polymers (Basel) 11 (4), 703.
doi:10.3390/polym11040703
Padoan, A., Bonfante, F., Pagliari, M., Bortolami, A., Negrini, D., Zuin, S.,
et al. (2020). Analytical and Clinical Performances of Five Immunoassays
for the Detection of SARS-CoV-2 Antibodies in Comparison with
Neutralization Activity. EBioMedicine 62, 103101. doi:10.1016/j.ebiom.
2020.103101
Perera, R. APM., Ko, R., Tsang, O. TY., Hui, D. SC, Kwan, M. YM., Brackman, C. J.,
et al. (2020). Evaluation of a SARS-CoV-2 Surrogate Virus Neutralization Test
for Detection of Antibody in Human, Canine, Cat and Hamster Sera. J. Clin.
Microbiol. 59 (2), e02504–20. doi:10.1128/JCM.02504-20
Piyush, R., Rajarshi, K., Chatterjee, A., Khan, R., and Ray, S. (2020). Nucleic AcidBased Therapy for Coronavirus Disease 2019. Heliyon 6 (9), e05007. doi:10.
1016/j.heliyon.2020.e05007
Plianwong, S., Thapa, B., Remant Bahadur, K.c., Kucharski, S., Rojanarata, T., and
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